NFE2L2 and ovarian cancer: Retinoic acid also has been informed to be improving the sensitivity of ovarian cancer cells to Trastuzumab and Pertuzumab[26] and of breast cancer cells to Cisplatin or Taxol[236] through NRF2 inhibition via a mechanism possibly involving RARs (38/243)[80,237].